<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02825134</url>
  </required_header>
  <id_info>
    <org_study_id>H-15019580</org_study_id>
    <nct_id>NCT02825134</nct_id>
  </id_info>
  <brief_title>Comparison of Transcatheter Versus Surgical Aortic Valve Replacement in Younger Low Surgical Risk Patients With Severe Aortic Stenosis</brief_title>
  <acronym>NOTION-2</acronym>
  <official_title>Nordic Aortic Valve Intervention Trial 2 - A Randomized Multicenter Comparison of Transcatheter Versus Surgical Aortic Valve Replacement in Younger Low Surgical Risk Patients With Severe Aortic Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Symetis SA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized clinical trial investigating transcatheter (TAVR) versus surgical (SAVR) aortic&#xD;
      valve replacement in patients 75 years of age or younger suffering from severe aortic valve&#xD;
      stenosis.&#xD;
&#xD;
      Study hypothesis: The clinical outcome (composite endpoint of all-cause mortality, MI and&#xD;
      stroke) obtained within 1 year after TAVR is non-inferior to SAVR.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND: Acquired aortic valve stenosis (AS) is the most common heart valve disease in the&#xD;
      Western World with a prevalence of 2-7% at the age of &gt;65 years. If untreated, it may lead to&#xD;
      heart failure and death. Surgical aortic valve replacement (SAVR) until recent years has been&#xD;
      the definitive treatment for patients with severe symptomatic AS. A less invasive&#xD;
      transcatheter aortic valve replacement (TAVR) has been developed and has been a treatment of&#xD;
      choice mostly for elderly high risk or inoperable patients. As TAVR technology is&#xD;
      continuously evolving and improving, it may be anticipated that it will become a valuable&#xD;
      alternative - and even the preferred choice of treatment - for younger, low-risk patients&#xD;
      with severe aortic valve stenosis in the near future. However, to date, there is no clinical&#xD;
      evidence that supports this hypothesis.&#xD;
&#xD;
      AIM: The purpose of the study is to compare TAVR and SAVR with regard to the intra- and&#xD;
      post-procedural morbidity and mortality rate, hospitalization length, functional capacity,&#xD;
      quality of life, and valvular prosthesis function in younger, low risk patients with severe&#xD;
      AS, scheduled for aortic valve replacement.&#xD;
&#xD;
      POPULATION: Younger low risk patients with severe aortic valve stenosis, which are scheduled&#xD;
      for aortic valve replacement using a bioprosthesis. Subjects fulfilling the inclusion&#xD;
      criteria, not having any exclusion criteria, and consenting to the trial will be randomized&#xD;
      1:1 to TAVR or SAVR with 496 patients in each group.&#xD;
&#xD;
      DESIGN: The study is a randomized clinical multicenter trial. Central randomization with&#xD;
      variable block size and stratification by gender and coronary comorbidity will be used. An&#xD;
      independent event committee blinded to treatment allocation will adjudicate safety endpoints.&#xD;
      Interim analysis is planned after the first 20 events included in the primary end-point&#xD;
      (all-cause mortality, stroke or myocardial infarction).&#xD;
&#xD;
      INTERVENTIONS:&#xD;
&#xD;
      TAVR: Any CE-Mark approved transcatheter aortic bioprosthesis may be used in the study, and&#xD;
      the choice is at the discretion of the local TAVR team. The transfemoral TAVR procedure may&#xD;
      be performed under general anaesthesia, local anaesthesia/conscious sedation, or local&#xD;
      anesthesia. Percutaneous coronary intervention (PCI) can be performed up to 30 days prior to&#xD;
      TAVR or as a hybrid procedure.&#xD;
&#xD;
      SAVR: The surgical SAVR technique follows standard protocol of the local department of&#xD;
      cardio-thoracic surgery. The operation is performed under general anesthesia, which follows&#xD;
      standard protocol of the department of anesthesiology. A commercial available surgical aortic&#xD;
      bioprosthesis at the surgeons discretion will be implanted. Concomitant coronary artery&#xD;
      bypass graft (CABG) surgery may be performed.&#xD;
&#xD;
      END POINTS: The primary endpoint is the composite rate of all-cause mortality death,&#xD;
      myocardial infarction and stroke within one year after the procedure (VARC-2 defintions).&#xD;
      Secondary endpoints are listed below. Follow-up will be performed after 30 days, 3 months, 1&#xD;
      year and yearly thereafter for a minimum of 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">June 2029</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite rate of all-cause mortality, stroke and rehospitalization (related to the procedure, the valve or heart failure) within one year after the procedure.</measure>
    <time_frame>at one year post-procedural.</time_frame>
    <description>VARC-2 definitions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device success (Absence of procedural mortality, correct positioning of a single valve into the proper anatomical location AND intended performanace of the prosthetic heart valve)</measure>
    <time_frame>at 30 days, 1 year and annually thereafter up to 10 years post-procedure</time_frame>
    <description>VARC-2 definitions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure time</measure>
    <time_frame>Intraoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of index hospitalization</measure>
    <time_frame>Number of days from admission to discharge (expected an averge of 7 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite rate of all-cause mortality, myocardial infarction and stroke</measure>
    <time_frame>at 30 days, 1 year and annually thereafter up to 10 years post-procedure</time_frame>
    <description>VARC-2 definitions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite rate of all-cause mortality, stroke and rehospitalization (related to the procedure, the valve or heart failure) at 30 days, 2 years and then yearly fot at least 10 years after the procedure (VARC-2 defintion).</measure>
    <time_frame>at 30 days, 2 year and annually thereafter up to 10 years post-procedure</time_frame>
    <description>VARC-2 definitions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>at 30 days, 1 year and annually thereafter up to 10 years post-procedure</time_frame>
    <description>VARC-2 definitions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke or TIA</measure>
    <time_frame>at 30 days, 1 year and annually thereafter up to 10 years post-procedure</time_frame>
    <description>VARC-2 definitions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding (life-threatening, major or minor)</measure>
    <time_frame>at 30 days, 1 year and annually thereafter up to 10 years post-procedure</time_frame>
    <description>VARC-2 definitions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular complication (major or minor)</measure>
    <time_frame>at 30 days, 1 year and annually thereafter up to 10 years post-procedure</time_frame>
    <description>VARC-2 defintions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute kidney injury (stage 1, 2 or 3)</measure>
    <time_frame>at 30 days, 1 year and annually thereafter up to 10 years post-procedure</time_frame>
    <description>VARC-2 defintions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic aortic bioprosthesis performance (degree of paravalvular leakage, valve area, mean gradient)</measure>
    <time_frame>Before discharge from index hospitalization (expected an average of 7 days), at 30 days, 1 year and annually thereafter up to 10 years post-procedure</time_frame>
    <description>VARC-2 definitions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA functional class</measure>
    <time_frame>at 30 days, 1 year and annually thereafter up to 10 years post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for permanent pacemaker</measure>
    <time_frame>at 30 days, 1 year and annually thereafter up to 10 years post-procedure</time_frame>
    <description>VARC-2 definitions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New onset atrial fibrillation captured on ECG</measure>
    <time_frame>Within discharge from index hospitalization (expected an average of 7 days), at 30 days, 1 year and annually thereafter up to 10 years post-procedure</time_frame>
    <description>VARC-2 definitions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-related valve safety (echocardiographic structural valve deterioration, prosthetic valve endocarditis, prosthetic valve thrombosis, thrombo-embolic events OR VARC bleeding)</measure>
    <time_frame>at 30 days, 1 year and annually thereafter up to 10 years post-procedure</time_frame>
    <description>VARC-2 definitions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricle remodeling as assesed by echocardiography</measure>
    <time_frame>at 30 days, 1 year and annually thereafter up to 10 years post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year overall costs in both treatment arms.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of stay on ICU after index procedure.</measure>
    <time_frame>Number of days from procedure to discharge from ICU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of early safety (all-cause mortality, all-stroke, life-threatening bleeding, acute kidney injury, coronary artery obstruction requiring intervention, Major vascular complication OR valve-related dysfunction requiring repeat procedure)</measure>
    <time_frame>at 30 days from index procedure</time_frame>
    <description>VARC-II definitions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical efficacy (all-cause mortality, all stroke, requiring hospitalization for valve-related symptoms or worsening congestive heart failure, NYHA class III or IV OR echocardiographic valve-related dysfunction)</measure>
    <time_frame>After 30 days of index procedure</time_frame>
    <description>VARC-II definitions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life change from baseline</measure>
    <time_frame>at 30 days, 1 year and annually thereafter up to 10 years post-procedure</time_frame>
    <description>assesed by SF-36v2, EQ-5d and KCCQ</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">372</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Heart Diseases</condition>
  <condition>Heart Valve Diseases</condition>
  <condition>Ventricular Outflow Obstruction</condition>
  <arm_group>
    <arm_group_label>Transcatheter aortic valve replacement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transcatheter aortic valve replacement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgical aortic valve replacement</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Surgical aortic valve replacement</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcatheter aortic valve replacement</intervention_name>
    <description>Retrograde transfemoral transcatheter aortic valve replacement with any CE mark approved aortic bioprosthesis with or without concomitant percutaneous coronary intervention.</description>
    <arm_group_label>Transcatheter aortic valve replacement</arm_group_label>
    <other_name>Transcatheter aortic valve implantation</other_name>
    <other_name>TAVR</other_name>
    <other_name>TAVI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Surgical aortic valve replacement</intervention_name>
    <description>Conventional surgical aortic valve replacement with a bioprosthesis using normothermic cardiopulmonary bypass and cold blood cardioplegia cardiac arrest with or without concomitant coronary artery bypass graft surgery.</description>
    <arm_group_label>Surgical aortic valve replacement</arm_group_label>
    <other_name>SAVR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 75 years or younger.&#xD;
&#xD;
          -  Severe calcific AS (Valve area &lt;1cm2 (or &lt;0.6 cm2/m2) AND one of the two following&#xD;
             criteria: mean gradient &gt;40mmHg or peak jet velocity &gt;4.0m/s, OR in presence of low&#xD;
             flow, low gradient with reduced or normal LVEF&lt;50%, a dobutamine stress echo should&#xD;
             verify true severe AS rather than pseudo-AS&#xD;
&#xD;
          -  Symptomatic with angina pectoris, dyspnea or exercise-induced syncope or near syncope&#xD;
             OR asymptomatic with abnormal exercise test showing symptoms on exercise clearly&#xD;
             related to AS or systolic LV dysfunction (LVEF &lt;50%) not due to another cause.&#xD;
&#xD;
          -  Anticipated usage of biological aortic valve prosthesis.&#xD;
&#xD;
          -  Low risk for conventional surgery (STS Score &lt;4%).&#xD;
&#xD;
          -  Suitable for both SAVR and transfemoral TAVR.&#xD;
&#xD;
          -  Life expectancy &gt;1 year after the intervention.&#xD;
&#xD;
          -  Informed consent to participate in the study after adequate information about the&#xD;
             study before randomization and intervention.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Coronary artery disease, not suitable for both percutaneous coronary intervention&#xD;
             (PCI) or coronary artery bypass graft surgery (CABG).&#xD;
&#xD;
          -  Coronary angiogram with a SYNTAX-score &gt;22.&#xD;
&#xD;
          -  LVEF &lt;25% without contractile reserve during dobutamine stress echocardiography.&#xD;
&#xD;
          -  Porcelain aorta, which prevents open-heart surgery.&#xD;
&#xD;
          -  Bicuspid valve with aorta ascendens diameter ≥45mm&#xD;
&#xD;
          -  Severe femoral, iliac or aortic atherosclerosis, calcification, coarctation, aneurysm&#xD;
             or tortuosity, which prevents transfemoral TAVR.&#xD;
&#xD;
          -  Need for open heart surgery other than SAVR with or without CABG.&#xD;
&#xD;
          -  Myocardial infarction within last 30 days&#xD;
&#xD;
          -  Stroke or TIA within the last 30 days. NOTION-2, 01. February 2017, version 5 9&#xD;
&#xD;
          -  Current endocarditis, intracardiac tumor, thrombus or vegetation.&#xD;
&#xD;
          -  Ongoing severe infection requiring intravenous antibiotics.&#xD;
&#xD;
          -  Unstable pre-procedural condition requiring intravenous inotropes or mechanical assist&#xD;
             device (IABP, Impella) on the day of intervention.&#xD;
&#xD;
          -  Kidney disease requiring dialysis or severely impaired lung function (FEV1 and/or&#xD;
             diffusion capacity &lt;40% of predicted).&#xD;
&#xD;
          -  Allergy to heparin, iodid contrast agent, warfarin, aspirin or clopidogrel.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars Søndergaard, MD; DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter S Olsen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lars Søndergaard, MD; DMSc</last_name>
    <email>Lars.Soendergaard.01@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rigshospitalet, Copenhagen University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Søndergaard</last_name>
      <email>Lars.Soendergaard.01@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Peter S Olsen</last_name>
      <email>Peter.Skov.Olsen@regionh.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Aarhus University hospital</name>
      <address>
        <city>Århus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evald H Christiansen</last_name>
      <email>evalchri@rm.dk</email>
    </contact>
    <contact_backup>
      <last_name>Kaj Erik Klaaborg</last_name>
      <email>kajklaab@rm.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>FI00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mika Laine</last_name>
      <email>mika.laine@hus.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oulu University Hospital</name>
      <address>
        <city>Oulu</city>
        <zip>90220</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timo Mäkikallio</last_name>
      <email>timo.makikallio@ppshp.fi</email>
    </contact>
    <contact_backup>
      <last_name>Vesa Anttila</last_name>
      <email>vesa.anttila@ppshp.fi</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikko Savotaus</last_name>
      <email>mikko.savontaus@tyks.fi</email>
    </contact>
    <contact_backup>
      <last_name>Markus Malmberg</last_name>
      <email>markus.malmberg@tyks.fi</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Landspital</name>
      <address>
        <city>Reykjavík</city>
        <zip>101</zip>
        <country>Iceland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingibjörg J Gudmundsdóttir</last_name>
      <email>ig@landspitali.is</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Öjvind Bleie</last_name>
      <email>oyvind.bleie@helse-bergen.no</email>
    </contact>
    <contact_backup>
      <last_name>Rune Haaverstad</last_name>
      <email>rune.haaverstad@helse-bergen.no</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>2009</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Aaberge</last_name>
      <email>laraabe@ous-hf.no</email>
    </contact>
    <contact_backup>
      <last_name>Kjell-Arne Rein</last_name>
      <email>kjrein@ous-hf.no</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Göteborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Truls Råmunddal</last_name>
      <email>Truls.Ramunddal@wlab.gu.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Rück</last_name>
      <email>andreas.ruck@karolinska.se</email>
    </contact>
    <contact_backup>
      <last_name>Göran Källner</last_name>
      <email>goran.kallner@karolinska.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Iceland</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 29, 2016</study_first_submitted>
  <study_first_submitted_qc>July 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2016</study_first_posted>
  <last_update_submitted>June 25, 2021</last_update_submitted>
  <last_update_submitted_qc>June 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Lars Soendergaard</investigator_full_name>
    <investigator_title>Professor of cardiology Lars Søndergaard; MD, DMSc</investigator_title>
  </responsible_party>
  <keyword>heart valve disease</keyword>
  <keyword>valvular bioprosthesis</keyword>
  <keyword>aortic valve replacement</keyword>
  <keyword>Randomized clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
    <mesh_term>Ventricular Outflow Obstruction</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

